Connect with us


Cannabidiol CBD for Depression



CBD Application: Depression

While most health afflictions result in sufferers feeling bad in some way, there is only one that is the embodiment of “feeling bad”: depression. Even those with debilitating illnesses can find reason for hope. But those suffering from depression deal with a condition that, at its core, is defined primarily by the absence of the capacity to experience hope.

In many ways, for this reason, it can be seen as the worst disease of all. This is all the more true by virtue of the fact that, for many, there is no cure and no real treatment that truly alleviates the worst of its symptoms.

However, new data is emerging that suggests CBD may offer a new path forward as we battle with this terrible affliction as a society. We will take a closer look at the situation below.

The Standard Approach

For most people suffering from depression, they are initially put on some sort of anti-depressant by a psychiatrist or doctor. That begins a wait and see period with the idea that more drastic steps will be engaged if that doesn’t help.

But, for many, that doesn’t do it. And subsequent treatments don’t move the needle much from there either.

However, the bigger point is this: even for those who find some help masking the symptoms with a drug, they are only getting a temporary escape without treating the underlying cause of the condition. This further introduces the concept of dependency and even addiction.

In short, anti-depressants are often highly addictive. Withdrawal symptoms when discontinued incorporate discombobulation, migraine, nausea and mental trips. Recent studies additionally propose a high rate of suicide while utilizing anti-depressants. You likewise need to take after a strict organization plan, and wrong dosages may cause sickness and unfavorable reactions.

Depression and the Benefits of CBD

Research on CBD as a treatment pathway has been heating up in recent years. We have witnessed some clear successes when applied to many different health conditions, with depression one of the latest additions to this list.

OBX mice – mice surgically changed to work as valid test subjects for this type of study – have been subjected to studies testing the impact of CBD on depression-like neurochemistry.

The results demonstrated a rapid bout of progress. Watching the mice 30 minutes after treatment with CBD showed a recognizable reduction in hyperactivity, which can be taken as a possible indication of a lessening of depression in people.

CBD (Cannabidiol) is one of around 70 active ingredients found in Cannabis. However, dissimilar to THC (Tetrahydrocannabinol), which is another active element of Cannabis and is a psychoactive substance, CBD is not psychoactive by any means. It has been demonstrated that CBD can actually balance the psychoactive nature of THC.

It has likewise been discovered useful in the treatment of depression. In addition, it is not addictive and seems to work faster than standard antidepressant drugs without the same level of side effects.

Concluding Thoughts

Perhaps most importantly, there is nothing to lose in trying CBD for depression. It has no habit-forming properties, won’t get you “stoned”, and doesn’t really carry any material risk of side-effects.

Naturally, as with any healthcare treatment choice, if you are pregnant or have any other serious disease, you should always consult a licensed physician to make sure CBD is right for your individual situation.

While CBD is fully legal across the US, there may be different laws in your local province or region of the world, and you should become familiar with how they apply to you.

Hopefully, as the evidence continues to pile up in favor of CBD, more research will ratify its utility as an effective option for those suffering from depression.

Continue Reading


WeedMD Inc (OTCMKTS:WDDMF) Rolls Out Its Color Cannabis Brand For Adults



WeedMD Inc (OTCMKTS:WDDMF) has announced the launch of its latest brand called Color Cannabis as a premium brand that targets adult users that want high-grade cannabis products.

The new Color Cannabis premium brand features numerous strains of cannabis that are presented in multiple formats. However, they are also developed such that they have a high level of quality as per the expectations of the target consumers. WeedMD’s new brand will only be available to a few distributors and retailers in Canada.

WeedMD plans to have the Color Cannabis-branded products in select stores as well as online availability by Mid-June. The company created the brand with a strategic aim at the diverse preference and tastes of the modern-day cannabis consumer.

“We worked with globally-renowned agency Sid Lee to launch Color – our first adult-use brand,” stated Brett Moon, the Senior Vice President of sales and marketing at WeedMD.

The Color Cannabis brand to mainly focus on a premium user experience

Mr. Moon also noted that Color Cannabis is designed to inspire customers to embrace life and their cannabis experience in personal and unique ways. Aside from being available in the form of dried premium flower, the new WeedMD brand also hosts new product formats over the next few months. Some of those products include gel capsules, oils and pre-rolls and they will be made available with the creation of more consumption formats.

WeedMD CEO Keith Merker stated that Color Cannabis’ goal is to grasp the progressive character, individuality, and imagination of cannabis users. The CEO noted that the goal of the brand is not to tell clients what they will feel but rather to experience the products for themselves. Merker also noted that the Color Cannabis launch represents a key milestone for the company.

WeedMD expects to juggle between the new adult cannabis brand and its medical cannabis pursuits. The company expects to produce about 150,000 kilograms through its 5.2 million square feet production capacity by 2020. The firm also expects to have enough room to handle production for medical cannabis, as well as recreational adult use. It plans to achieve this through its indoor and outdoor growth facilities.

Continue Reading


HempAmericana Inc. (OTCMKTS:HMPQ) CEO Issues Explains The Company’s Expansion



HempAmericana Inc. (OTCMKTS:HMPQ) CEO has issued a letter to shareholders addressing the expansion of the company following string orders.

HempAmericana has begun bottling of full-spectrum CBD distillate

In the letter to shareholders, the CEO indicated that the company has begun establishing growth momentum in its CBD oil production as well as the distribution business. The CEO stated that the company has started bottling of 500 mg as well as 1000 mg full spectrum CBD distillate in its ultramodern CBD production and extraction facility in Augusta Maine.

He added that the company’s initial production is expected to be around 2,000 bottles per day which will be increased gradually to around 8,000 bottles a day to meet demand. Currently, the company has more than 50,000 full spectrum distillate bottles that are ready to be shipped with tens of thousands expected to follow.

HempAmericana is equally bottling a 250 mg potency that is suitable for the CBD-for-pets market. On the high end, the CEO indicated that the company is bottling 2500 mg and 5000 mg but he asserted that they have the potential of replicating any formula.

The CEO further went on to explain that production will be distributed under the company’s proprietary brand “Weed Got Oil.” He added that the company is also pursuing an opportunity in the white label market for the quality full-spectrum distillate CBD Oil. Currently, there are over 400 brands in the CBD market with the majority turning to high capacity producers such as HempAmericana to build product inventory.

Relationship with Eagle Hemp

The company recently announced a relationship with Florida based Eagle Hemp for an initial purchase order as well as the establishment of connections for more orders in the future. The company anticipates strong demand that includes compensation for more production of CBD oil as well as its bottling technology. The first order will bring the company significant revenue input at no associated costs to labeling, bottling, and shipping.

The company’s production facility and lab are currently operating well with two bottling machines in operation. The CEO said that once they distill the interest into purchase orders they will communicate to shareholders.

Continue Reading


Medmen Enterprises Inc. (OTCMKTS:MMNFF) Expands Its Footprint In California With Acquisition Of One Love



MedMen Enterprises Inc. (OTCMKTS:MMNFF) has announced the signing of a definitive agreement for the acquisition of 100% interest in MattnJeremy, Inc. One Love Beach Club.

Acquisition of One Love

The acquisition enhances the company’s California footprint by adding a premier location that is positioned strategically between its LAX and Santa Ana locations. The One Love Beach Club is currently on a run-rate of around $6 million in gross revenue and has an unaudited EBITDA margin of about 29%.

MedMen CEO Adam Bierman stated that they were delighted to have Long Beach on bard as part of the MedMen family as the company continues its growth in the world’s leading cannabis market.

One love was founded back in 2009 and it is located in Long Beach at 2767 E Broadway between Belmont Shore and Downtown some blocks from the beach. Long Beach is located 20 miles from Los Angeles and it is the third largest city in Southern California behind San Diego and Los Angeles with a population of almost half a million.

The city is a prime location that offers attractions, oceanfront hotels, events, recreation activities, shopping, nightly entertainment, restaurants as well as art and culture. According to the Long Beach Convention & Visitors Bureau in 2018 there were approximately 7.9 million visitors who visited the city to attend various events and attractions.

The One Love owner and operator Abrams Family indicated that it had been exciting to have served the Long Beach community for the last ten years adding that they were looking forward to MedMen to continue offering the community with premium cannabis.

Details of the transaction

According to the details of the transaction MedMen is expected to pay around $13 million of which $1 million will be in cash at closing of the deal and $2 million in deferred cash. The rest of the $10 million shall be fulfilled in Class B Subordinate Voting shares. Completion of the transactions depends on regulatory approval by state and local authorities as well as other routine closing conditions. The deal is expected to be closed within 45 days.

Continue Reading

Trending Stories